Supplementary Materials & Methods from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304672

October 8, 2025

Supplementary Materials & Methods from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

RAS pathway inhibitors demonstrate effectiveness against oncogenic KRAS variants in various cancer types.
Patient-derived spheroids offer a relevant model, showcasing promising results with targeted agents.
Combining RAS pathway inhibitors with targeted therapies could lead to improved treatment options for patients.
Further investigation is necessary to validate these findings across diverse cancer types.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Supplementary analysis reveals RAS pathway inhibitors enhance effects of targeted agents in patient-derived spheroids, suggesting new treatment strategies.

Abstract

Supplementary Materials & Methods

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bc8 https://doi.org/10.1158/2767-9764.30304672

View Full Paper

Ask AI

Bookmark

Share

Supplementary Materials & Methods from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Materials & Methods from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading